Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.

Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH.

Mol Cell Biol. 2001 Aug;21(16):5471-7.

2.

Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.

Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, van Helvoort A, de Jong MC, Hooijberg JH, Mol CA, van der Linden M, de Vree JM, van der Valk P, Elferink RP, Borst P, Scheper RJ.

Cancer Res. 2000 Sep 15;60(18):5269-77.

3.

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476-81.

4.

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

Wijnholds J, deLange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P.

J Clin Invest. 2000 Feb;105(3):279-85.

5.

Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.

Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, Borst P.

Nat Med. 1997 Nov;3(11):1275-9.

PMID:
9359705
6.

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4028-33.

7.
8.
9.

Multidrug resistance and the role of P-glycoprotein knockout mice.

Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1295-8. Review.

PMID:
7577039
10.

Characterization of the promoter region of the human MDR3 P-glycoprotein gene.

Smit JJ, Mol CA, van Deemter L, Wagenaar E, Schinkel AH, Borst P.

Biochim Biophys Acta. 1995 Mar 14;1261(1):44-56.

PMID:
7893760
11.

Tissue distribution of the human MDR3 P-glycoprotein.

Smit JJ, Schinkel AH, Mol CA, Majoor D, Mooi WJ, Jongsma AP, Lincke CR, Borst P.

Lab Invest. 1994 Nov;71(5):638-49. Erratum in: Lab Invest 1995 Mar;72(3):followi.

PMID:
7734012
12.

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al.

Cell. 1994 May 20;77(4):491-502.

PMID:
7910522
13.

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al.

Cell. 1993 Nov 5;75(3):451-62.

PMID:
8106172
14.

Stable transformation of Trypanosoma brucei.

ten Asbroek AL, Mol CA, Kieft R, Borst P.

Mol Biochem Parasitol. 1993 May;59(1):133-42.

PMID:
8515775

Supplemental Content

Support Center